secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scilex Holding Co (SCLX)
CIK:        0001820190
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0001193125-25-043338
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scilex sells 4% royalty on Gloperba/Elyxyb to defer Tranche B amortization to 2026
--------------------------------------------------------------------------------

- Sold 4% of aggregate net sales of Gloperba and Elyxyb to Oramed, Murchinson, and 3i; consideration is deferral of First Amortization Payment on Tranche B Notes to Oct 8, 2026.
- Entered Security Agreement granting first-priority liens on royalty collateral; Note Agent's lien subordinated to second priority.
- Licensed exclusive worldwide ex-US rights to Gloperba to RoyaltyVest Ltd on 50/50 net revenue split.
- Amended ZTlido Royalty Agreement to allow asset sale without consent if all Debt Instrument obligations are paid in full.
- Transaction closed Feb 28, 2025; grants Royalty and Exclusive Rights under January 2, 2025 Tranche B Consents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1820190/000119312525043338/0001193125-25-043338-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1820190/000119312525043338/d864577d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-043338

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer